The poor efficacy of chimeric antigen receptor T-cell therapy (CAR T) for solid tumors is due to insufficient CAR T cell tumor infiltration, in vivo expansion, persistence, and effector function, as ...
A laboratory study out of Roswell Park Comprehensive Cancer Center outlines a new way to boost the effectiveness of chimeric antigen receptor (CAR) T-cell therapy in solid-tumor cancers, resulting in ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Frederick Locke, ...
Adoptive cellular immunotherapy with engineered CAR-T cells has shown durable clinical responses in hematological malignancies 1; however, relapse remains a challenge due to factors such as tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results